Research programme: CNS disorders therapies - (now Teva Pharmaceutical Industries)/Transition Therapeutics

Drug Profile

Research programme: CNS disorders therapies - (now Teva Pharmaceutical Industries)/Transition Therapeutics

Latest Information Update: 27 Oct 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cephalon; Transition Therapeutics
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders

Most Recent Events

  • 14 Apr 2010 Discontinued - Preclinical for CNS disorders in USA (unspecified route)
  • 07 Nov 2005 Protana has been acquired and merged into Transition Therapeutics
  • 18 Aug 2004 MDS Proteomics is now called Protana
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top